CFRX - ContraFect Corp Stock Price, Fair Value and News

$0.030.00 (0.00%)

Market Closed

CFRX Stock Valuation Analysis

Valuation

Max Portfolio %

CFRX Price Action

CFRX RSI Chart

CFRX Stock Valuation Analysis

Valuation

Max Portfolio %

CFRX Valuation

CFRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CFRX Fundamentals

CFRX Earnings

CFRX Profitability

CFRX Investor Care

Revenue & Growth

About ContraFect Corp

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.

CEO	Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.
WEBSITE	contrafect.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	23